BioAdaptives (OTC: BDPT) has detailed the scientific strategy behind its Xcellara cellular wellness platform, which is set to launch its first commercial product, XcellaraHeart, on August 1. The platform integrates a stem/progenitor cell mobilization base—supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells—with tissue-specific ingredients designed to direct those cells to targeted areas.
According to the company, XcellaraHeart pairs the Xcellara base with Tanshinone IIA, a compound derived from Danshen that has been studied for its role in cardiovascular SDF-1α/CXCR4 signaling. This approach aims to support the body’s natural signaling pathways and enhance cellular homing to cardiac tissue. The company plans to expand the platform with additional formulas targeting joint mobility, skin health, cognitive wellness, and metabolic resilience, using the same supply-and-direction development model.
BioAdaptives emphasizes that the Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks, with zero adverse effects on over twenty blood parameters. The company intends to provide a complete scientific evidence dossier for the XcellaraHeart formulation at products.xcellara.com/science, which separates demonstrated human clinical research on the Xcellara base from published research on Tanshinone IIA and the product-development rationale for combining them.
The announcement comes as the company seeks to establish its platform in the dietary supplement market, focusing on cellular wellness and targeted tissue support. The implications of this strategy could resonate with consumers seeking science-backed supplements for heart health and other wellness categories. By leveraging clinical trial data and a novel approach to cellular mobilization, BioAdaptives aims to differentiate its products in a crowded market.
For more information on the Xcellara product line and the science behind it, visit products.xcellara.com. The full press release is available at https://ibn.fm/YxZaA.
